Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension
2019 ◽
Vol 29
(06)
◽
pp. 849-851
◽
Keyword(s):
AbstractSelexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.
2015 ◽
Vol 25
(8)
◽
pp. 939-944
2018 ◽
Vol 8
(3)
◽
pp. 204589401879358
◽
2019 ◽
Vol 18
(6)
◽
pp. 80-87
◽
2014 ◽
Vol 13
(1)
◽
pp. 21-26
◽